Enhanced expression and significance of glycosylphosphatidylinositol anchor attachment protein 1 in colorectal cancer

G. Chen1,2, S.Y. Li2, H.Y. Cai2 and F.Y. Zuo2

1Department of Postgraduate, Third Military Medical University, Shapingba District, Chongqing, China
2Department of General Surgery, General Hospital of PLA Beijing Military Command, East District, Beijing, China

Corresponding author: S.Y. Li
E-mail: shiyong_li010@163.com

Received August 26, 2013
Accepted October 28, 2013
Published January 21, 2014

ABSTRACT. The aim of this study was to investigate the expression of glycosylphosphatidylinositol anchor attachment protein 1 (GPAA1) and its significance in patients with colorectal cancer. Fifty-two patients with primary colorectal cancer were included in this study. GPAA1 expression was detected by immunohistochemistry, reverse transcription-polymerase chain reaction, and Western blot analysis. A cell invasion assay was performed by the transwell method. The interacting proteins of GPAA1 were detected by co-immunoprecipitation and matrix assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF/TOF-MS). The expression of GPAA1 mRNA and protein in primary colorectal tumor tissues and liver metastasis tissues was significantly higher than that in normal mucosa tissues (P < 0.01). The number of highly expressing GPAA1 cells penetrating the Matrigel membrane was significantly higher than that of mildly expressing GPAA1 cells (P < 0.05). The results of co-immunoprecipitation and MALDI-TOF/TOF-MS confirmed the identity of the protein. GPAA1
is highly expressed in patients with colorectal cancer, which indicates that it might play an important role in the proliferation, invasion, and metastasis of colorectal cancer.

Key words: GPAA1; Colorectal cancer; MALDI-TOF/TOF-MS; Co-immunoprecipitation

INTRODUCTION

We previously reported 10 proteins that interact with the FasL protein using proteomics techniques, including anchor attachment (AN), metallothionein 1K, metallothionein 1G, metallothionein 2A, cathepsin B, fatty acid synthase, interferon alpha inducible protein 27, phospholipid scramblase, Ser/Thr-like kinase, and fiber microfilament protein-5 (Zuo et al., 2004, 2006). On the liver cell membrane, phosphatidylinositol was found to combine with AN to form glycosylphosphatidylinositol anchor attachment protein 1 (GPAA1), and the overexpression of GPAA1 was closely related to the occurrence and development of liver cancer (Ho et al., 2006). In this study, we detected the expression of GPAA1 in patients with colorectal cancer to explore the relationship between GPAA1 and the proliferation, invasion, and metastasis of colorectal cancer.

MATERIAL AND METHODS

Source of specimens

The primary colorectal cancer tissues of 52 patients were obtained from the General Surgery Department, General Hospital of Military Region, Beijing. None of the patients received preoperative radiochemotherapy, and their average age was 58.5 years. The primary colorectal tumor tissue, normal colorectal mucosa tissue, and liver metastasis tissue were removed quickly and stored in liquid nitrogen.

Immunohistochemistry

The mouse anti-human GPAA1 polyclonal antibody was purchased from Santa Cruz Biotechnology, and the antibody was diluted at 1:200 to obtain the working concentration. The streptomycin avidin-catalase method was used for immunohistochemical staining, and normal calf serum was used as the negative control. The results were determined as follows: no coloring cells, -; 10-30% coloring cells, +; 30-50% coloring cells, ++; >50% coloring cells, +++.

“-” and “+” were classified as negative expression, whereas “++” and “+++” were classified as positive expression.

Real-time quantitative polymerase chain reaction (PCR)

Total RNA was extracted with Trizol, and the primers were synthesized by Aoke Biological Technology Company with the following sequences: GPAA1-F (5'-TCT CAA GGC TCT GGA ACT G-3') and GPAA1-R (5'-GCC CCA CAC CCT GTG ATG-3'). The reference gene
was 3-glyceraldehyde phosphate dehydrogenase (GAPDH). The reaction consisted of an initial denaturation step at 95°C for 5 min, 40 thermal cycles, and an elongation step at 70°C for 7 min. Each of the 40 thermal cycles consisted of a denaturing step at 95°C for 30 s, an annealing step at 50°C for 30 s, and an elongation step at 70°C for 30 s. The relative expression of GPAA-1 was calculated according to the formula: $2^{-\Delta\Delta Ct}$, where $\Delta Ct = [Ct(GPAA1) - Ct(GAPDH)]_{\text{experimental group}} - [Ct(GPAA1) - Ct(GAPDH)]_{\text{control group}}$. Each sample was set in four replicate wells.

**Western blot**

One hundred milligrams primary colorectal tumor tissue, normal colorectal mucosa tissue, and liver metastasis tissue were ground in liquid nitrogen, and then the lysis buffer was added and the concentration of proteins was adjusted to 2.5 µg/µL with the bicinchoninic assay. Next, the proteins were boiled at 100°C for 5 min, centrifuged at 12,000 g for 5 min, and 50 µg proteins were loaded. The electrophoresis conditions were as follows: the stacking gel was set at 80 V for 20 min, and the separation gel was set at 100 V. When bromophenol blue reached the bottom of the gel, semi-dry electrophoresis was performed (30 mA, 90 min). After blocking, the GPAA-1 antibody was incubated overnight at 4°C, the membrane was washed with Tris-buff ered saline with Tween, and incubated with horseradish peroxidase-labeled secondary antibody for 30 min. The membrane was developed with ECL luminous liquid. Using the Image-Pro Plus software to analyze the gray scale of the GPAA-1 and β-actin genes, the relative expression of the GPAA-1 protein was determined as the ratio of GPAA-1 and β-actin gray scale.

**Cell invasion assay**

The primary cells of colorectal cancer tissues highly expressing GPAA1 (cell_high-GPAA1) and mildly expressing GPAA1 (cell_low-GPAA1) were cultured (Chen et al., 2011). First, the Matrigel was coated on the microporous membrane of a Boyden transwell at 37°C for 30 min, and then the transwell was placed on a 24-well plate. Then, 0.4 mL (7.5 x 10^3) cell_high-GPAA1 and cell_low-GPAA1 were added to the upper chamber, and 0.6 mL medium was added to the lower chamber. There were 3 wells in each group. Cells were cultured with 5% CO₂ at 37°C for 72 h, the membrane was removed and fixed with 75% methanol for 45 min, stained with hematoxylin overnight, and the number of cells penetrating the membrane was counted under a microscope. The number of cells penetrating the membrane without Matrigel was used as the control group (Negus and Balkwill, 1996).

**Detection of protein interacting with GPAA1 by co-immunoprecipitation**

The protein sample was diluted to 1 mg/mL with phosphate-buffered saline and placed on ice, 50% protein A-Agarose was added to incubate for 1 h, centrifuged at 4°C, the supernatant was collected, and 5 µg GPAA1 antibody was added to incubate overnight at 4°C. Fifty microliters 50% protein A-Agarose was added again, incubated on ice for 1 h, centrifuged at 4°C, and the supernatant was collected. Next, the protein A-Agarose-antibody-protein compound was washed three times with protein extraction reagent, denatured for 5 min, and the supernatant was again collected by centrifugation. The unknown protein was detected by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The gel was stained with Coomassie Blue.
Identification of unknown protein with matrix assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF/TOF-MS)

The gel was cut into 1-2 mm³ sections, and then destained with solution containing 50% acetonitrile and 25 mM NH₄HCO₃. Next, the gel was dried in a vacuum centrifuge drier for 20 min, and trypsin solution was added to the gel at 37°C for 20 h. The supernatant was collected after digestion, and then 50 µL 5% trifluoroacetic acid (TFA) was added to the gel, incubated at 40°C for 1 h, and the supernatant was collected again. Next, 20 µL 5% TFA and 50 µL 50% acetonitrile were added to the gel at 30°C for 1 h, and the supernatant was collected again. Finally, all supernatants were merged together and dried by centrifugation. MALDI-TOF/TOF-MS was performed on an AB4700 mass spectrometer (Bruker Dalton) with the following settings: 20 kV, positive ions, CCA matrix, the internal standard used was the 2163.05 trypsin autotomy peak as calibration standards, and the external standard used was based on the mixture of seven standard peptides. The data were compared to the National Center for Biotechnology Information (NCBI) database with the Mascot software (http://www.matrixscience.co.uk).

Statistical analysis

The data were analyzed with the SPSS 13.0 software. For enumeration data, the χ² test was used, and measurement data were analyzed with the Student t-test; P < 0.05 was considered to be statistically significant.

RESULTS

Immunohistochemical detection

Fifty-two colorectal cancer samples were subjected to immunohistochemistry, and GPAA1 was found to be located in the cytoplasm (Figure 1). The positive expression rate of GPAA1 in normal colorectal mucosa tissue, primary colorectal tumor tissue, and liver metastasis tissue were 21.15% (11/52), 55.76% (29/52), and 72.73% (8/11), respectively. The expression of GPAA1 in primary colorectal tumor tissues and liver metastasis tissues (χ² = 9.15) was significantly higher than that in normal mucosa tissue (χ² = 11.7406 and 9.1474, P < 0.01); there was no significant difference in the expression of GPAA1 between liver metastasis and tumor tissues (χ² = 0.4912, P > 0.05).

Expression of the GPAA1 gene

The results of real-time quantitative PCR showed that the expression of GPAA1 mRNA in primary colorectal tumor tissues (13.76 ± 7.451) and liver metastasis tissues (19.32 ± 11.243) was significantly higher than that in normal mucosa tissue (6.24 ± 4.768; t = 3.5832 and 3.6723, P < 0.01), and the expression of GPAA1 mRNA in liver metastasis tissues was higher than that in tumor tissues (t = 2.96, P < 0.05) (Figure 2).

Expression of the GPAA1 protein

The results of Western blot analysis showed that the molecular weight of GPAA1 was
between 70 and 62 kDa. The expressions of the GPAA1 protein in primary colorectal tumor tissues (1.112 ± 0.240) and liver metastasis tissues (1.482 ± 0.342) were significantly higher than that in normal mucosa tissue (0.434 ± 0.106) (t = 11.546 and 12.066, P < 0.01), and the expression of the GPAA1 protein in liver metastasis tissues was higher than that in tumor tissues (t = 3.951, P < 0.01) (Figure 3).

**Figure 1.** Immunohistochemical detection of GPAA1 in colorectal cancer. A. Normal colonic mucosa; B. normal liver; C. primary colorectal cancer; D. hepatic metastases.

![Image 1](image1.png)

**Figure 2.** Expression of GPAA1 gene by RT-PCR. **P < 0.01 compared to normal colonic mucosa. *P < 0.05 compared to primary colorectal cancer.**
Results of the cell invasion assay

The number of cells with high-GPAA1 expression penetrating the Matrigel membrane was $12.9 \pm 2.4$, which was significantly higher than that of cells with low-GPAA1 expression ($7.7 \pm 2.1$), and the difference was statistically significant ($t = 3.3541, P < 0.05$) (Figure 4).

Figure 3. Expression of GPAA1 protein. Lane 1 = Hepatic metastases; lane 2 = primary colorectal cancer; lane 3 = normal colonic mucosa. ** and # $P < 0.01$ compared to normal colonic mucosa.

Figure 4. Results of cell invasion assay. *$P < 0.05$ compared to low expression GPAA1.
Results of co-immunoprecipitation and MALDI-TOF/TOF-MS

As shown in Figure 5, both the high and low expression GPAA1 groups expressed a protein between 70 and 62 kDa. The results of MALDI-TOF/TOF-MS confirmed the identity of this protein.

**Figure 5.** Results of coimmunoprecipitation and MALDI-TOF/TOF-MS.

Relationship between GPAA1 gene expression and pathological characteristics of colorectal cancer

According to the ratio of GPAA1 mRNA expression in colorectal tumor tissues and normal colorectal mucosa tissues, 52 samples were assigned to two groups: the high-expression group (N = 31) and the low-expression group (N = 21). The expression level of GPAA1 mRNA was closely correlated with the differentiation degree, but not with age, gender, or Dukes staging (Table 1).

<table>
<thead>
<tr>
<th></th>
<th>High expression of GPAA1 mRNA (N = 31)</th>
<th>Low expression of GPAA1 mRNA (N = 21)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;60</td>
<td>8</td>
<td>7</td>
</tr>
<tr>
<td>≤60</td>
<td>23</td>
<td>14</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>25</td>
<td>16</td>
</tr>
<tr>
<td>Female</td>
<td>6</td>
<td>5</td>
</tr>
<tr>
<td>TDD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HD</td>
<td>5</td>
<td>10*</td>
</tr>
<tr>
<td>MD</td>
<td>11</td>
<td>7</td>
</tr>
<tr>
<td>LD</td>
<td>15</td>
<td>4*</td>
</tr>
<tr>
<td>Dukes stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A-B stage</td>
<td>12</td>
<td>11</td>
</tr>
<tr>
<td>C-D stage</td>
<td>19</td>
<td>10</td>
</tr>
</tbody>
</table>

*χ² = 7.2005, P < 0.05. TDD = tissue differentiation degree; HD = high differentiation; MD = middle differentiation; LD = low differentiation.
DISCUSSION

The glycosylphosphatidylinositol-anchored protein (GPI-AP) is a protein anchored at the surface of the eukaryotic cell membrane through the carboxyl terminus of GPI, which plays an important role in immune recognition, as a complement regulator, and in transmembrane signal transduction. The GPAA1 complex is composed of an anchor attachment protein and GPI, which is an important part of the glycosylphosphatidylinositol transamidase complex (GPIT), which is itself composed of 5 subunits: PIG-U, PIG-T, GPAA1, PIG-S, and GPI (Fraering et al., 2001; Ohishi et al., 2001; Vainauskas et al., 2002; Vainauskas and Menon, 2004). Nagpal et al. (2008) reported that the subunits of GPIT were increased in a variety of tumors. For example, PIG-U was expressed in bladder cancer as an oncogene, and PIG-T and GPAA1 were expressed in breast cancer (Wu et al., 2006). The enhanced expression of GPIT subunits was associated with the proliferation and invasion of tumor cells.

In this study, we detected the expression of GPAA1 with immunohistochemistry, real-time quantitative PCR, and Western blot analysis. The results showed that the expression of GPAA1 was higher in primary colorectal cancer tissues and liver metastasis tissues than in normal mucosa tissues, suggesting that GPAA1 plays an important role in tumor occurrence and development. Our results also showed that the high expression of GPAA1 mRNA was related to the degree of tumor differentiation. Tumors with poor differentiation are strongly aggressive; therefore, this result indicated that the high expression of GPAA1 mRNA was related to tumor invasion, and the expression of GPAA1 in liver metastasis confirmed this view. In addition, the in vitro invasion assay showed that more cells with high expression of GPAA1 penetrated the Matrigel membrane compared to cells with low expression of GPAA1. All of these results showed that the enhanced expression of GPAA1 was closely associated with the occurrence, invasion, and metastasis of colorectal cancer.

GPAA1 is located in human chromosome 8q24.3, and the oncogene c-myc is located in chromosome 8q24.1. The c-myc gene is activated through chromosomal translocation rearrangement, combines with chromosomal DNA, and plays a role in cell growth, differentiation, and malignant transformation (Chana et al., 2002). Amplification of the c-myc gene was also observed in human colon cancer (Sánchez-Pernaute et al., 2005). As the GPAA1 and c-myc genes are located in the same chromosome, both of their expressions were enhanced in colorectal cancer, and the c-myc gene is the target gene of the Wnt signaling pathway (Behrens and Lustig, 2004; Chen et al., 2009). We speculate that GPAA1 might regulate c-myc gene expression through the Wnt signaling pathway. Our study will provide a new foundation and method for the treatment of colorectal cancer; however, the mechanism of GPAA1 effects on tumor proliferation and invasion still needs further study.

ACKNOWLEDGMENTS

Research supported by the research grant #30772118 from National Natural Sciences Foundation of China, Beijing.

REFERENCES

GPAA1 in colorectal cancer


